KALA BIO (NASDAQ:KALA) Major Shareholder Bros. Advisors Lp Baker Sells 513,607 Shares

KALA BIO, Inc. (NASDAQ:KALA) major shareholder Bros. Advisors Lp Baker sold 513,607 shares of the company’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $1.38, for a total transaction of $708,777.66. Following the completion of the transaction, the insider directly owned 46,480 shares in the company, valued at $64,142.40. This trade represents a 91.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Tuesday, September 30th, Bros. Advisors Lp Baker sold 216,801 shares of KALA BIO stock. The shares were sold at an average price of $1.60, for a total value of $346,881.60.

KALA BIO Stock Performance

Shares of NASDAQ KALA opened at $1.54 on Friday. The company has a debt-to-equity ratio of 3.19, a current ratio of 2.10 and a quick ratio of 2.10. KALA BIO, Inc. has a one year low of $1.10 and a one year high of $20.60. The business’s 50-day moving average price is $10.90 and its two-hundred day moving average price is $6.73. The company has a market capitalization of $10.81 million, a P/E ratio of -0.23 and a beta of -2.10.

KALA BIO (NASDAQ:KALA) last announced its quarterly earnings results on Friday, August 8th. The company reported ($1.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.82) by $0.11. Analysts anticipate that KALA BIO, Inc. will post -10.84 earnings per share for the current fiscal year.

Institutional Trading of KALA BIO

A number of large investors have recently bought and sold shares of KALA. ADAR1 Capital Management LLC lifted its holdings in shares of KALA BIO by 35.7% during the first quarter. ADAR1 Capital Management LLC now owns 298,955 shares of the company’s stock valued at $1,713,000 after acquiring an additional 78,582 shares during the period. Readystate Asset Management LP bought a new stake in shares of KALA BIO in the 1st quarter worth about $243,000. AIGH Capital Management LLC increased its position in shares of KALA BIO by 61.9% during the 1st quarter. AIGH Capital Management LLC now owns 196,350 shares of the company’s stock worth $1,125,000 after purchasing an additional 75,048 shares in the last quarter. Woodline Partners LP acquired a new stake in shares of KALA BIO during the first quarter worth approximately $1,483,000. Finally, Geode Capital Management LLC raised its stake in shares of KALA BIO by 2.8% in the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company’s stock valued at $268,000 after acquiring an additional 1,534 shares during the last quarter. 24.61% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on KALA shares. Oppenheimer increased their price target on shares of KALA BIO from $15.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, September 11th. Wall Street Zen cut shares of KALA BIO from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. HC Wainwright restated a “neutral” rating on shares of KALA BIO in a report on Monday, September 29th. Mizuho set a $1.50 price target on KALA BIO in a research report on Tuesday. Finally, Lifesci Capital lowered KALA BIO from a “strong-buy” rating to a “hold” rating in a report on Monday, September 29th. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, KALA BIO presently has a consensus rating of “Hold” and an average price target of $20.38.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.